POSB93 Conversion from Subcutaneous Trastuzumab to Trastuzumab-Dkst in Metastatic Breast Cancer: Comparative Cost-Efficiency Modelling between US and France
Jan 1, 2022, 00:00
10.1016/j.jval.2021.11.366
https://www.valueinhealthjournal.com/article/S1098-3015(21)02161-6/fulltext
Title :
POSB93 Conversion from Subcutaneous Trastuzumab to Trastuzumab-Dkst in Metastatic Breast Cancer: Comparative Cost-Efficiency Modelling between US and France
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(21)02161-6&doi=10.1016/j.jval.2021.11.366
First page :
Section Title :
Open access? :
No
Section Order :
11141